Generated Narrative: Citation 267247

url: Citation 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.

identifier: FEvIR Object Identifier/267247, https://pubmed.ncbi.nlm.nih.gov/15832493, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.47

version: 2.0.0-ballot

title: 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.

status: Active

date: 2024-11-01 10:20:00+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2005-05-18

lastReviewDate: 2019-11-09

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2005-04-19 09:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2005-05-19 09:00:00+0000

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2005-04-19 09:00:00+0000

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/15832493, https://doi.org/10.2165/00024677-200201060-00006

Titles

-	Type	Language	Text
*	Primary title	English	Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.

Abstracts

-

Text

*

<AbstractText Label="UNLABELLED">Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production and increases glucose clearance in patients with type 2 diabetes mellitus. Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Double-blind trials of 8 to 26 weeks of rosiglitazone 4 or 8 mg/day monotherapy indicate significant decreases in fasting plasma glucose (-2 to -3 mmol/L with 8 mg/day) and glycosylated hemoglobin levels [HbA(1c); -0.6 to -0.7% (-0.8 to -1.1% in drug-naive patients) with 8 mg/day]. Significant decreases in hyperglycemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulfonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Efficacy was maintained in trials of < or =2 years, and was also apparent in various ethnic subgroups, elderly patients and both obese and nonobese patients. Rosiglitazone is currently not indicated in combination with injected insulin. It should be administered in conjunction with diet and exercise regimens. Rosiglitazone is generally well tolerated. Despite rare individual reports of liver function abnormalities in rosiglitazone recipients, the incidence of these in clinical trials (< or =2 years' duration) was similar to that in placebo and active comparator groups. Fluid retention associated with rosiglitazone may be the cause of the increased incidence of anemia in clinical trials, and also means that patients should be monitored for signs of heart failure during therapy. Although bodyweight is increased overall with rosiglitazone therapy, increases are in subcutaneous, not visceral, fat; hepatic fat is decreased. The pharmacokinetic profile of rosiglitazone is not substantially altered by age or renal impairment, nor are there important drug interactions. Rosiglitazone is not indicated in patients with active liver disease or increased liver enzymes. CONCLUSIONS: Oral rosiglitazone 4 or 8 mg/day provides significant antihyperglycemic efficacy and is generally well tolerated, both as monotherapy and in combination with other antihyperglycemic agents, in patients with type 2 diabetes mellitus who do not have active liver disease. Long-term data are required before conclusions can be drawn about the clinical significance of positive changes to surrogate markers of cardiovascular disease risk and improvements to pancreatic beta-cell function. Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus.

publicationForm

publishedIn

type: Periodical

identifier: Print ISSN Type/1175-6349, ISOAbbreviation/Treat Endocrinol, ISSN Linking/1175-6349, Medline Title Abbreviation/Treat Endocrinol, NLM Unique ID/101132977

title: Treatments in endocrinology

publisherLocation: New Zealand

citedMedium: Print

volume: 1

issue: 6

articleDate: 2002

publicationDateText: 2002

language: English

pageString: 411-4

WebLocations

-	Classifier	Url
*	Abstract	https://pubmed.ncbi.nlm.nih.gov/15832493/

classification

type: Publishing Model

classifier: Print

classification

type: Chemical

classifier: Hypoglycemic Agents, Thiazolidinediones, Rosiglitazone

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Journal Article, Review

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Wagstaff AJ

forenameInitials: AJ

affiliation: Adis International Inc., Langhorne, Pennsylvania, USA. demail@adis.com

entry

contributor: Goa KL

forenameInitials: KL

Generated Narrative: Practitioner #contributor0

name: Antona J Wagstaff

Generated Narrative: Practitioner #contributor1

name: Karen L Goa

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Diabetes Mellitus, Type 2

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Hypoglycemic Agents

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Rosiglitazone

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Thiazolidinediones

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	Yes